Neuvivo

Neuvivo is a private, pre-revenue biotech advancing NP001, a novel immunotherapy for ALS. The company has reached alignment with the FDA on an approval pathway, indicating a clear regulatory roadmap for its lead program. Founded in 2015, Neuvivo is built on a neuro-immunologic hypothesis for ALS, aiming to modulate inflammation at the neuromuscular junction to slow disease progression and preserve vital functions like breathing. Its leadership combines scientific, clinical, and biopharmaceutical development expertise.

Neuro-immunology platform targeting dysfunctional innate immunity at the neuromuscular junction. Proposed mechanism involves supplementing taurine chloramine to rebalance pro- and anti-inflammatory processes and halt motor neuron destruction.

Competes in the ALS therapeutic space against approved drugs (riluzole, edaravone, AMX0035) and numerous investigational agents targeting diverse mechanisms. Its differentiation as a first-in-class immunotherapy targeting innate immune dysfunction at the neuromuscular junction is its key competitive angle.